Doripenem: mikrobiologicheskie osobennosti i klinicheskie aspekty primeneniya u bol'nykh nozokomial'noy infektsiey (obzor literatury)


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

The review details the doripenem - antibiotic from the carbapenem group, registered and approved for use in the Russian Federation in 2008. Foreign publications presented convincing evidence of the clinical and microbiological efficacy of doripenem in patients with nosocomial pneumonia, including ventilator-associated pneumonia. Comparative studies demonstrate that doripenem is no less effective drug than other representatives of the carbapenem group, fluoroquinolones and inhibitor-protected penicillins in patients with complicated abdominal infections, urinary tract infections. Some studies revealed certain advantages of doripenem over other carbapenems in terms of antimicrobial activity against P. aeruginosa.

Full Text

Restricted Access

References

  1. Агеевец В.А., Партина И.В., Лисицына Е.С., Батыршин И.М.,Попенко Л.Н.,Шляпников С.А, Ильина Е.Н., Сидоренко С.В. Чувствительность грамотрицательных бактерий, продуцентов карбапенемаз, к антибиотикам различных групп. Антибиотики и химиотерапия. 2013;58(3-4):3-6.
  2. Гилберт Д., Меллеринг Р., Элиопулос Дж., Чемберс Г., Сааг М. Антимикробная терапия по Джею Сэнфорду. М., 2013. 640 с.
  3. Ортенберг Э.А, Шафеева Ю.Э., Кирушок Г.И., Хохлявин Р.Л., Шень Н.П. Карбапенемы в многопрофильном стационаре: некоторые клинические и экономические аспекты. Клиническая микробиология и антимикробная химиотерапия. 2014;16(1):33-8.
  4. Стецюк О.У., Андреева И.В., Козлов Р.С. Новый карбапенемный антибиотик дорипенем: перспективы применения в клинической практике. Клиническая микробиология и антимикробная химиотерапия. 2008;10(3):245-60.
  5. Яковлев В.П. Дорипенем - новый антибиотик группы карбапенемов. Клиническая фармакология и терапия. 2008;17(4):1-9.
  6. Anderson D.L. Doripenem. Drugs Today. 2006;42(6)399-404.
  7. Ayalew K., Nambiar S.,Yasinskaya Y., Jantausch B.A. Carbapenems in pediatrics. Ther. Drug Monit. 2003;25:593-99.
  8. Bhavnani S.M., Hammel J.P., Cirincione B.B. Wikler M.A., Ambrose P.G. Use of pharmacokineticpharmacodinamic target attainment analyses to support phase 2 and 3 dosing strategies for doripenem. Antimicrob. Agents Chemother. 2005;49:3944-47.
  9. Cannon J.P., Lee T.A., Clark N.M., Setlak P., Grim S.A. The risk of seizures among the carbapenems: a meta-analysis. J. Antimicrob. Chemother. 2014;69(8):2043-55.
  10. Chastre J, Wunderink R., Prokocimer P., Lee M., Kaniga K., Friedland I. Efficacy and safety of intravenous infusion of doripenem versus imipenem in ventilatorassociated pneumonia: a multicenter, randomized study. Crit. Care Med. 2008;36(4):1089-96.
  11. Curran M., Simpson D., Perry C. Ertapenem: a review of its use in the management of bacterial infections. Drugs. 2003;63:1855-78.
  12. Firsov A.A., Gilbert D., Greer K., Portnoy Y.A., Zinner S.H. Comparative parmacodynamics and antimutant pjtential of doripenem and imipenem with ciprofloxacin-resistant Pseudomonas aeruginosa in an in vitro model. Antimicrob. Agents Chemother. 2012;56:1223-28.
  13. Goldstein E.J., Snydman D.R. Intra-abdominal infections review of the bacteriology, antimicrobial susceptibility and the role ertapenem in their therapy. J. Antimicrob. Chemother. 2004;53(Suppl 2):ii29-36.
  14. Horiuchi M., Kimura M., Tokumura M., Hasebe N., Arai T., Abe K. Absence of convulsive liability of doripenem, a new carbapenem antibiotic, in comparison with beta-lactam antibiotics. Toxicology. 2006;222(1-2):114-24.
  15. Hsaiky L., Murray K. P, Kokoska L., Desai N., Cha R. Standard Versus Prolonged Doripenem Infusion for Treatment of Gram-Negative Infections. Ann. Pharmacother. 2013; 47:999-1006.
  16. Ikawa K., Morikawa N., Urakawa N., Ikeda K., Ohge H., Sueda T. Peritoneal penetration of doripenem after intravenous administration in abdominal-surgery patients. J. Antimicrob. Chemother. 2007;60:1395-97.
  17. Jenkins S.G., Fisher A.C., Peterson J.A., Nicholson S.C., Kaniga K. Meta-analysis of doripenem vs comparators in patients with pseudomonas infections enrolled in four phase III efficacy and safety clinical trials. Curr. Med. Res. Opin. 2009;25(12):3029-36.
  18. Kamidono S., Arakawa S., Hirose T., et al. Double-blind, controlled study to evaluate safety and efficacy of doripenem and meropenem in patients with complicated urinary tract infection [in Japanese]. Jpn. J. Chemother. 2005; 53(Suppl 1):244-59.
  19. Kiratisin P., Keel K., Nicolau D.R. Pharmacodinamic profiling of doripenem, imipenem and meropenem against prevalent Gramnegative organisms the Asia-Pacific region. Int. J. Antimicrob. Agents 2013;41:47-51.
  20. Kollef M.H., Chastre J., Clavel M., Restrepo M.I., MichielsB., Kaniga K, CirilloI.,KimkoH., RedmanR. A randomized trial of 7-day doripenem versus 10-day imipenem-cilastatin for ventilator-associated pneumonia. Crit. Care. 2012;16:R218.
  21. Lucasti C.,Jasovich A., Umeh O.,JiangJ.,Kaniga K., Riedland I.F. Efficacy and Tolerability of IV Doripenem Versus Meropenem in Adults with Complicated Intra-Abdominal Infection: A Phase III, Prospective, Multicenter, Randomized, Double-Blind, Noninferiority Study. Clin. Ther. 2008;30(5):868-83.
  22. Luyt C.-E., Aubry A., Lu Q., Bœchot N., Brossier F., Brisson H., Rouby J.J., Trouillet J.L., Combes A., Jarlier V., Chastre J. Pneumonia aeruginosa Ventilator-Associated Treat Patients with Pseudomonas. Antimicrob. Agents Chemother. 2014;58(3):1372-80.
  23. Malafaia O., Umeh O., Jiang J. Doripenem versus meropenem for the treatment of complicated intra-abdominal infections [Abstract No.L-1564b plus poster]. 47th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2006; San Francisco, CA, USA; 2006.
  24. Mouton J.W., Touzw D.J., Horrevorts A.M., Vinks A.A. Comparative pharmacokinetics of the carbapenems: clinical implications. Clin. Pharmacokinet. 2000;39:185-201.
  25. Mushtaq S., Ge Y., Livermore D.M. Comparative activities of doripenem versus isolates, mutants, and transconjugants of Enterobacteriaceae and Acinetobacter spp. with characterized beta-lactamases. Antimicrob. Agents Chemother 2004;48:1313-19.
  26. Mustafa M., Chan W.M., Lee C., Harijanto E., Loo C.M., Van Kinh N., Anh N.D., Garcia J. A PROspective study on the Usage patterns of Doripenem in the Asia-Pacific region (PROUD study). Int. J. Antimicrob. Agents. 2014;43(4):353-60.
  27. Naber K.G., Llorens L., Kaniga K., Kotey P., Hedrich D., Redman R. Intravenous doripenem at 500 milligrams versus levofloxacin at 250 milligrams, with an option to switch to oral therapy, for treatment of complicated lower urinary tract infection and pyelonephritis. Antimicrob. Agents Chemother. 2009;53(9): 3782-92.
  28. Nicolau D.P., Carmeli Y. Grank C.W., Goff D.A., Graber C.J., Lima A. L., Goldstein E.J.C. Carbapenem stewardship: does ertapenem affects Pseudomonas susceptibility to other carbapenems? A review of the evidence. Int. J. Antimicrob. Agents 2012;39:11-5.
  29. Norrby S.R. Carbapenems. Med. Clin. North Am. 1995;79:745-59.
  30. Paterson D.L., Pestel D.D. Doripenem. Rev. Antiinfect. Agents. 2009;49:292-98.
  31. Queenan A.M., Shang W., Bush K., Flamm R. Hydrolysis parameters for doripenem, meropenem, and imipenem tested with ,tnf-lactamases of molecular classes A to D. In; Program and Abstracts of the 18th European Congress of Clinical Microbiology and Infectious Diseases. April 19-22. 2008. Barcelona, Spain.
  32. Question and answers on the review of Doribax. European Medicines Agency. 2012 (yune).
  33. Rea-Neto A, Niederman M., Lobo S.M., Schroeder E., Lee M., Kaniga K., Ketter N., Prokocimer P., Friedland I. Efficacy and safety of doripenem versus piperacillin/tazobactam in nosocomial pneumonia: a randomized, open-label, multicenter study. Curr. Med. Res. Opin. 2008;24(7):2113-26.
  34. Redman R., File T.M. Safety of Intravenous Infusion of Doripenem. Clin. Infect. Dis. 2009;49:S28-35.
  35. Samtani M.N., Flamm R., Kaniga K., Nandy P. Pharmacokinetic-pharmacodynamic- model-guided doripenem dosing in critically ill patients. Antimicrob. Agents Chemother. 2010;54:2360-64.
  36. Singh K.P., Li G., Mitrani-Gold F.S., Kurtinecz M., Wetherington J., Tomayko J.F, Mundya L.M. Systematic Review and Meta-Analysis of Antimicrobial Treatment Effect Estimation in Complicated Urinary Tract Infection. Antimicrob. Agents Chemother. 2013;57(11): 5284-90.
  37. Tazuma S., Igarashi Y., Inui K., Ohara H., Tsuyuguchi T., Ryozawa S.; The BTI Therapy Research Group. Clinical efficacy of intravenous doripenem in patients with acute biliary tract infection: a multicenter, randomized, controlled trial with imipenem/cilastatin as comparator. J. Gastroenterol. 2015;50(2):221-29.
  38. Tsuji M., Ishii Y., Ohno A., Miyazaki S., Yamaguchi K. In vitro and in vivo antibacterial activitiesof S-4661, a new carbapenem. Antimicrob. Agents Chemother. 2004;48:1313-19.
  39. Tzouvelekis L.S., Markogiannakis A., Psichogiou M., Tassios P.T., Daikos G.L. Carbapenemases in Klebsiella pneumoniae and other Enterobacteriaceae: an evolving crisis of global dimensions. Clin. Microbiol. Rev. 2012;25:682-707.
  40. Van Wart S.A., Andes D.R., Ambrose P.G., Bhavnani S.M. Pharmacokinetic-pharmacodynamic modeling to support doripenem dose regimen optimization for critically ill patients. Diagn. Microbiol. Infect. Dis. 2009;63(4):409-14.
  41. Yohnson A.P., Woodford N. Global spread of antibiotic resistance: the example of Naw Delhi metallo-beta-lactamase ( NDM)-mediated carbapenem resistance. J. Med. Microbiol. 2013;62:499-513.
  42. Yones R.N., Huynh H.K., Biedenbach D.J. Aktivities of doripenem (S-4661) against drug-resistant clinical patogenes. Antimicrob. Agents Chemother. 2004:48:31-40.
  43. Yoshida I., Yamaguchi T., Kudo R. Antimicrobial susceptibility of clinical isolates of aerobic grampositive cocci and anaerobic bacteria in 2008. Jpn. J. Antibiotics. 2012;65(1)49-72.
  44. Yoshida I., Yamaguchi T, Kudo R. Antimicrobial susceptibilityof clinical isolates of aerobic gramnegative bacteria in 2008. Jpn. J. Antibiot. 2012;65(1):73-96.
  45. Zhanel G.G., Wiebe R., Dilay L., Thompson K., Rubinstein E., Hoban D.J. Comparative review of the carbapenems. Drugs. 2007; 67(7):1027-52.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies